EGFR and non-small cell lung carcinoma: Data derived from subgroup analysis of large clinical trials have revealed that different agents seemed to have different impacts, but in general, the clinical activity of ICI monotherapy in first-line treatment of EGFR-mutant NSCLC was limited (87–90, 107).